1 Restriction Spectrum Imaging as a quantitative biomarker for prostate cancer with 2 reliable positive predictive value

3

Mariluz Rojo Domingo^{1,2}, Deondre D Do^{1,2}, Christopher C Conlin³, Aditya Bagrodia⁴, 4 5 Tristan Barrett⁵, Madison T Baxter², Matthew Cooperberg⁶, Felix Feng⁷, Michael E Hahn³, Mukesh Harisinghani⁸, Gary Hollenberg⁹, Juan Javier-Desloges⁴, Karoline Kallis², Sophia 6 7 Kamran¹⁰, Christopher J Kane⁴, Dimitri Kessler⁵, Joshua Kuperman², Kang-Lung Lee⁵, 8 Jonathan Levine⁶, Michael A Liss¹¹, Daniel JA Margolis¹², Ian Matthews², Paul M Murphy³, 9 Nabih Nakrour⁸, Michael Ohliger¹³, Courtney Ollison², Thomas Osinski¹⁴, Anthony James 10 Pamatmat¹⁴, Isabella R Pompa⁸, Rebecca Rakow-Penner³, Jacob L Roberts⁴, Karan 11 Santhosh¹⁵, Ahmed S Shabaik¹⁶, Yuze Song^{2,17}, David Song¹⁴, Clare M. Tempany⁸, Natasha 12 Wehrli¹², Eric P. Weinberg⁹, Sean Woolen¹³, George Xu², Allison Y Zhong², Anders M

- 13 Dale^{3,18,19}, Tyler M Seibert^{1,2,3}
- 14
- 15 ¹Department of Bioengineering, University of California San Diego, La Jolla, CA, USA
- 16 ²Department of Radiation Medicine, University of California San Diego, La Jolla, CA, USA
- 17 ³Department of Radiology, University of California San Diego, La Jolla, CA, USA
- 18 ⁴Department of Urology, University of California San Diego, La Jolla, CA, USA
- 19 ⁵Department of Radiology, University of Cambridge, Cambridge, United Kingdom
- 20 ⁶Department of Urology, University of California San Francisco, San Francisco, CA, USA
- 21 ⁷Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
- 22 ⁸Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
- 23 *Department of Clinical Imaging Sciences, University of Rochester Medical Center, Rochester, NY, USA
- ²⁴ ¹⁰Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
- 25 ¹¹Department of Urology, University of Texas Health Sciences Center San Antonio, San Antonio, TX, USA
- 26 ¹²Department of Radiology, Cornell University, Ithaca, NY, USA
- ¹³Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco,
 CA, USA
- 29 ¹⁴Department of Urology, University of Rochester Medical Center, Rochester, NY, USA
- 30 ¹⁵Department of Computer Science, University of California San Diego, La Jolla, CA, USA
- 31 ¹⁶Department of Pathology, University of California San Diego, La Jolla, CA, USA
- 32 ¹⁷Department of Electrical and Computer Engineering, University of California San Diego, La Jolla, CA, USA
- 33 ¹⁸Department of Neurosciences, University of California San Diego, La Jolla, CA, USA
- 34 ¹⁹Halıcıoğlu Data Science Institute, University of California San Diego, La Jolla, CA, USA

35 Abstract

Background and Objective. Positive predictive value of PI-RADS for clinically significant prostate cancer (csPCa, grade group [GG]>2) varies widely between institutions and radiologists. The Restriction Spectrum Imaging restriction score (RSIrs) is a metric derived from diffusion MRI that could be an objectively interpretable biomarker for csPCa.

41 <u>Methods</u>. In patients scanned for suspected or known csPCa at 7 centers, we calculated

42 patient-level csPCa probability based on maximum RSIrs in the prostate, without relying

43 on subjectively defined lesions. We used area under the ROC curve (AUC) to compare

patient-level csPCa detection for RSIrs, ADC, and PI-RADS. Finally, we combined RSIrs
 with clinical risk factors via multivariable regression, training in a single-center cohort

46 and testing in an independent, multi-center dataset.

Key Findings and Limitations. Among all patients (n=1892), probability of csPCa 47 48 increased with higher RSIrs. GG≥4 csPCa was most common in patients with very high 49 RSIrs. Among biopsy-naïve patients (n=877), AUCs for GG≥2 vs. non-csPCa were 0.73 50 (0.69-0.76), 0.54 (0.50-0.57), and 0.75 (0.71-0.78) for RSIrs, ADC, and PI-RADS, 51 respectively. RSIrs significantly outperformed ADC (p<0.01) and was comparable to PI-52 RADS (p=0.31). The combination of RSIrs and PI-RADS outperformed either alone. 53 Combining RSIrs with PI-RADS, age, and PSA density in a multivariable model achieved 54 the best discrimination of csPCa.

55 <u>Conclusions and Clinical Implications</u>. RSIrs is an accurate and reliable quantitative
 56 biomarker that performs better than conventional ADC and comparably to expert 57 defined PI-RADS for patient-level detection of csPCa. RSIrs provides objective estimates
 58 of probability of csPCa that do not require radiology expertise.
 59

60 Introduction

61 Multiparametric magnetic resonance imaging (mpMRI) has reduced unnecessary biopsies, decreased overdiagnosis of indolent disease, and improved detection of 62 clinically significant prostate cancer (csPCa, grade group (GG) ≥ 2)¹⁻³. In clinical practice, 63 64 mpMRI is interpreted qualitatively using the Prostate Imaging Reporting & Data System (PI-RADS v2.1). While negative predictive value (NPV) using PI-RADS is high and fairly 65 consistent⁴, positive predictive value (PPV) for csPCa varies widely across institutions 66 and between radiologists^{5,6}. The heavy dependence on user expertise and the variability 67 68 across readers leads to healthcare disparities by limiting access to high-quality MRI. A 69 quantitative imaging biomarker could help move prostate MRI toward objective 70 interpretation and yield consistent PPV for csPCa-positive biopsy.

71

72 Diffusion-weighted MRI is the most important mpMRI sequence for csPCa detection in 73 the PI-RADS system⁷. However, the conventional quantitative metric for diffusion-74 weighted MRI, apparent diffusion coefficient (ADC), is based on an unrealistically 75 simplistic model that assumes uniform free diffusion of water molecules in the prostate. 76 Restriction Spectrum Imaging (RSI) is a more advanced diffusion-weighted MRI 77 technique that yields a quantitative biomarker (RSI restriction score, or RSIrs) designed 78 to highlight csPCa. In prior retrospective single-center studies, we showed that RSIrs 79 reduced the number of false positives compared to ADC and outperformed ADC for 80 voxel-level and patient-level detection of csPCa^{8,9}. A prospective study found that 81 radiation oncologists were much more accurate in outlining csPCa on MRI when using 82 RSIrs than when using conventional MRI alone¹⁰.

83

84 In this study, we evaluate RSIrs as a generalizable tool for patient-level csPCa 85 detection-with objective interpretation-in data from multiple imaging protocols, 86 scanners, vendors, and centers. We also evaluate the accuracy of RSIrs in challenging 87 scenarios: csPCa detection among younger patients¹¹ and within the transition zone 88 (TZ)^{12,13}. Lastly, we investigate integrating RSIrs with other clinical parameters, such as 89 age and prostate specific antigen density (PSAD) to yield objective estimates of csPCa 90 probability that could serve as a standardized reference for assessing prostate MRIs, 91 independent of radiologist expertise.

92

93 Methods

94 <u>Study Population</u>

95 The data for this study come from seven imaging centers participating in the Quantitative 96 Prostate Imaging Consortium (QPIC): the Center for Translational Imaging and Precision 97 Medicine at the University of California San Diego (CTIPM), UC San Diego Health (UCSD), 98 University of California San Francisco (UCSF), Harvard University affiliated 99 Massachusetts General Hospital (MGH), University of Rochester Medical Center (URMC), University of Texas Health Sciences Center San Antonio (UTHSCSA), and 100 101 University of Cambridge (Cambridge). The study was approved by each center's 102 institutional review board (IRB). Data were collected prospectively at UCSD, UTHSCSA, 103 and Cambridge; data were collected retrospectively at the other centers. Participants at 104 UTHSCSA and Cambridge provided written informed consent, while a waiver of consent 105 was approved by the respective IRBs at the other centers for secondary use of routine 106 clinical data. We included individuals aged ≥18 who underwent an MRI for suspected or

- 107 known csPCa between January of 2016 and March of 2024. Patients were excluded in the
- 108 event of prior treatment of prostate cancer (PCa) or if there was no available biopsy result
- 109 from within 6 months of a positive MRI scan (PI-RADS \geq 3). Patients with metal implants
- 110 $\,$ were also excluded because of the potential to cause significant artifact in MRI.
- 111 Diagnosis of csPCa was confirmed on biopsy histopathology per clinical routine at each 112 center.
- 112 113
- 114 RSI data acquisition, processing, and modeling
- 115 Image post-processing for RSI data included correction for background noise, gradient
- 116 nonlinearities, and eddy currents¹⁴⁻¹⁶. Data acquired at CTIPM were also corrected for
- 117 distortion caused by B_0 inhomogeneity¹⁷. Automated prostate contours were obtained
- 118 using an FDA-cleared commercial product (OnQ Prostate, CorTechs.ai, San Diego, CA).
- 119 In the RSI framework, diffusion MRI signal is modeled as a combination of exponential 120 decays corresponding to four diffusion microcompartments (intracellular, extracellular, free diffusion, and vascular flow) within each voxel¹⁸. The RSIrs biomarker is the 121 122 intracellular signal at a given voxel normalized by median T_2 -weighted signal in the 123 prostate and multiplied by 1,000 for convenience. RSIrs is highest where intracellular 124 diffusion restriction (hypercellularity) and nucleus-to-cytoplasm ratio are high, both 125 features characteristic of csPCa. Maximum RSIrs is the highest RSIrs value within the 126 prostate^{8-10,14,18-20}. Additional details are provided in Supplementary Table 1.

127 Patient-level detection of csPCa

- 128 For objective and reliable interpretation of MRI results independent of radiologist 129 expertise, risk of csPCa must be determined without subjective lesion delineation. Thus, 130 we assessed csPCa classification performance using maximum RSIrs, which only 131 requires automated segmentation of the prostate. We plotted histograms of maximum 132 RSIrs by csPCa status and obtained the probability (PPV) of csPCa and high-grade csPCa 133 for RSIrs strata by dividing the number of GG \geq 2 and GG \geq 3 cases, respectively, by the total 134 number of patients for each bin. Bins spanned 50 RSIrs units, and adjacent bins were 135 combined for illustration purposes if PPV were similar. Pathologic GG is a major prognostic factor for patients with csPCa²¹: GG2 cancer with low-volume Gleason 136 137 pattern 4 generally poses little risk and may be safely monitored²², while GG3-5 cancers 138 are more critical to detect and treat early because of their higher metastatic potential²³. 139 We showed the GG distribution within each RSIrs stratum among patients who were
- 140 biopsy-naïve at time of MRI.

141 To evaluate patient-level detection of csPCa over a range of possible operating points, we plotted the receiver operating characteristic (ROC) curves with csPCa as the outcome 142 of interest. For comparison, we used minimum ADC within the prostate and the highest 143 144 PI-RADS category for each patient. PI-RADS reporting was performed per clinical routine 145 by experienced, board-certified, fellowship-trained radiologists. We calculated the area 146 under the curve (AUC) with 95% confidence intervals from 10,000-bootstrapping 147 samples and compared bootstrap AUC differences (α =0.05). We repeated these 148 analyses stratified by GG (i.e., GG2 vs. non-csPCa, GG3 vs. non-csPCa, etc.). We also 149 evaluated csPCa detection in challenging subsets: patients with TZ lesions and patients 150 with age <60 years.

152 We used multivariable logistic regression models to combine RSIrs with other routinely 153 available clinical risk factors that physicians may consider in biopsy decisions. We 154 incorporated age, prostate-specific antigen (PSA) level, and PSA density (PSAD). We also 155 evaluated combining these objective variables with expert interpretation of MRI (PI-RADS). Black or African American men are much more likely to develop PCa^{24,25}, so we 156 157 evaluated self-reported race as an additional predictor. We trained the models using 158 UCSD Health data collected on two GE Healthcare Discovery MR750 scanners. The 159 models were tested in remaining patients from all cohorts who were biopsy-naïve at time 160 of MRI and who received a biopsy after MRI. We tested the multivariable models for 161 patient-level detection of csPCa (csPCa vs. non-csPCa) and by GG. We evaluated 162 models with different predictors: (1) age and PSA, which are available before an MRI 163 scan; (2) age and PSAD, which can be computed once MRI is performed; (3) age, PSAD, 164 and RSIrs; (4) RSIrs and PI-RADS, to see if better than either alone; (5) age, PSAD, RSIrs, and PI-RADS; and (6) age, race, PSAD, RSIrs, and PI-RADS. 165

166167 Results

168 Patient-level detection of csPCa

169 1892 patients met the criteria for inclusion (Table 1). Data were acquired using 7 distinct
 170 acquisition protocols, 2 scanner vendors, 3 scanner models, and 17 MRI scanners

- 171 (Supplementary Table 2).
- 172

173 Probability of csPCa increased with higher RSIrs. High-grade (GG4-5) csPCa was

proportionally more common among those with highest RSIrs (Figure 1). For RSIrs>500,

there was 80% probability of csPCa found on biopsy and 64% probability of GG \geq 3 PCa,

- 176whereas for RSIrs<200, patients had 12% probability of csPCa and only 6% probability of</th>177GG \geq 3 PCa. RSIrs and ADC maps are shown for three representative patients in Figure 2.
- 178

179 ROC curve analysis demonstrated that RSIrs was superior to ADC and comparable to PI-

- 180 RADS for patient-level detection of csPCa (Figure 3). Among 877 biopsy-naïve patients
 181 who underwent biopsy after MRI, median AUC for GG≥2 vs. non-csPCa was 0.73 (0.69-
- 182 0.76) for RSIrs, 0.54 (0.50-0.57) for ADC, and 0.75 (0.71-0.78) for PI-RADS. RSIrs
- 183 significantly outperformed ADC (*p*<0.01) and was comparable to PI-RADS (*p*=0.31).
- 184

185When comparing GG≥3 to non-csPCa (i.e., excluding GG2), median AUCs were 0.76186(0.72-0.80) for RSIrs, 0.55 (0.50-0.60) for ADC, and 0.79 (0.76-0.82) for PI-RADS. RSIrs187significantly outperformed ADC (p<0.01) and was comparable to PI-RADS (p=0.14). Both188RSIrs and PI-RADS showed partial specificity for high-grade csPCa, with higher189performance for detection of GG3 and GG4-5 than for GG2 (Figure 3 and Supplementary190Table 3).

191

192 RSIrs performed similarly to expert PI-RADS in patients with lesions in the TZ (p=0.90) and 193 PZ (p=0.07). RSIrs performed similarly to PI-RADS in patients <60 years (p=0.12) and >60

194 years (*p*=0.11). Subset analyses by race were limited by small sample size for most

- 195 groups (Supplementary Table 3).
- 196 Multivariable integrated risk

197 Models to combine predictor variables were trained in 554 patients, including 232 with 198 no biopsy but presumed free of csPCa (PI-RADS 1-2 and PSAD≤0.15)²⁶ and excluding 199 patients that did not have a PI-RADS score available. Models were tested in an 200 independent dataset from multiple institutions with 664 patients, all biopsy naïve before 201 MRI and with biopsy confirmation of csPCa status. The combination of RSIrs and PI-RADS 202 outperformed either alone (p < 0.01 and p = 0.01, respectively), and a model of age, PSAD, 203 PI-RADS, and RSIrs achieved the best discrimination of csPCa, outperforming RSIrs 204 alone and PI-RADS alone (p < 0.01; Table 2). Addition of race did not significantly improve 205 performance in any of the multivariable models.

206

207 Discussion

208 We assessed RSIrs as an objective MRI biomarker for detecting csPCa at the patient 209 level. In contrast to ADC, which typically becomes clinically useful after a radiologist 210 identifies a suspicious lesion, RSIrs assessed automatically within the entire prostate 211 performed comparably to expert PI-RADS for patient-level detection of csPCa in a large, 212 heterogenous and multi-center dataset. Moreover, RSIrs performs best for the high-213 grade cancers that are also most important to detect. An automated measurement of 214 RSIrs can give physicians and patients an objective and reliable estimate of the likelihood 215 of csPCa or high-grade csPCa.

216

217 Subspecialist radiologists are often at elite centers that provide care for only a small 218 proportion of patients. A quantitative biomarker could contribute to making accurate 219 prostate MRI accessible to patients who do not receive their care at these elite centers. 220 The PPV of RSIrs is inherently reproducible for a given scan, as it is calculated objectively 221 from the MRI. Use of RSIrs, then, could make prostate MRI more reliable and more readily 222 interpretable for referring physicians and their patients. By addressing the variable PPV 223 of PI-RADS and reducing dependence on reader expertise, implementation of objective 224 biomarkers could increase health equity in the PCa diagnostic pathway. 225

226 RSIrs requires only an RSI MRI acquisition lasting 2-3 minutes and a T_2 -weighted MRI 227 acquisition (another 2-3 minutes). Thus, 4-6 minutes of scan time can yield an 228 automated RSIrs biomarker with performance comparable to expert radiologists' 229 evaluations of a full PI-RADS mpMRI scan. RSI acquisitions are compatible with standard 230 clinical scanners and do not require administration of intravenous contrast. Installing the 231 RSI acquisition protocols on modern scanners involves simply saving protocol files on 232 the scanner. Calculation of RSIrs can be performed by software on a desktop personal 233 computer.

234

235 Maximum RSIrs is a quantitative biomarker that is readily interpretable. Thus, use of 236 RSIrs could establish a floor for performance of csPCa detection regardless of available 237 radiology expertise. Radiologist interpretation of MRI remains important for evaluation of 238 secondary questions: extraprostatic extension, tumor proximity to the neurovascular 239 bundles, and seminal vesicle involvement. However, these latter questions are mostly 240 relevant only after a biopsy-confirmed diagnosis of csPCa is established and therefore 241 apply to a smaller subset of patients. For the initial question of whether csPCa is likely to 242 be found on biopsy, RSIrs performs comparably to expert-defined PI-RADS, and the 243 combination of both is better than either alone.

244 We focused this study on patient-level csPCa detection. Another important role of MRI is tumor localization for targeted biopsy²⁷⁻³²and radiotherapy planning³³⁻³⁵. Radiologist-245 246 defined lesion segmentations were not available to perform lesion-level analysis of this 247 large dataset. The commercial software our centers use to delineate biopsy targets does 248 not permit export of those segmentations and automatically deletes them to make room 249 for future studies. In any event, expert-defined lesions are subjectively identified, thus 250 undermining the primary goal of the study to consider approaches independent of 251 radiologist expertise. Prior work, though, has shown that RSIrs maps are useful for 252 localization of csPCa (Figure 2). There is a strong correlation between RSI and csPCa on 253 whole-mount histopathology, and RSIrs is superior to ADC for voxel-level detection of 254 csPCa^{9,36}. Further, a prospective study evaluated radiation oncologists' ability to 255 delineate csPCa on MRI; these non-radiologists were much more accurate when using 256 RSIrs maps vs. conventional MRI alone, confirming that RSIrs maps reflect the location 257 of csPCa and make it more apparent to non-experts¹⁰.

258

Automated and quantitative MRI approaches may help alleviate the growing shortage of expert radiologists relative to an anticipated surge in PCa diagnoses³⁷. Other MRI biomarkers have also shown potential clinical utility in prior studies^{38,39}. To our knowledge, the present study is the largest and most comprehensive validation of a quantitative MRI biomarker for patient-level csPCa detection. Ongoing research evaluates whether incorporating RSIrs into radiomics-based analysis and deep-learning artificial intelligence tools could further enhance detection performance.

266

267 Our study has some limitations. First, biopsy techniques are prone to sampling error and 268 therefore represent an imperfect gold standard. Nonetheless, most patients here 269 underwent both systematic and targeted biopsy, which is the current clinical standard and captures most csPCa^{4,28,29,40}. Consistent with clinical guidelines, patients with non-270 271 suspicious prostate MRI typically did not undergo biopsy, raising the possibility of false 272 negatives on PI-RADS, though the risk of this is low⁴. Also, patients with hip implants 273 were excluded from this study; the effect of metal artifact on RSIrs is the subject of 274 ongoing research.

275

276 Conclusions

In heterogeneous data from multiple imaging centers, RSIrs proved to be a quantitative
imaging biomarker that performs comparably to expert-defined PI-RADS for patient-level
detection of csPCa. With only 4-6 minutes of scan time on standard clinical MRI
platforms, RSIrs gives objective estimates of probability of csPCa, thus addressing the
current clinical challenge of unreliable PPV with PI-RADS.

283 References

- Filson CP, Natarajan S, Margolis DJA, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. *Cancer*. 2016;122(6):884-892. doi:10.1002/cncr.29874
- Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
 JAMA. 2015;313(4):390-397. doi:10.1001/jama.2014.17942
- Yaxley AJ, Yaxley JW, Thangasamy IA, Ballard E, Pokorny MR. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions. *BJU Int*. 2017;120 Suppl 3:43-50. doi:10.1111/bju.13971
- 4. Sathianathen NJ, Omer A, Harriss E, et al. Negative Predictive Value of
- 296 Multiparametric Magnetic Resonance Imaging in the Detection of Clinically
- 297 Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era:
- A Systematic Review and Meta-analysis. *Eur Urol*. 2020;78(3):402-414.
- 299 doi:10.1016/j.eururo.2020.03.048
- S. Westphalen AC, McCulloch CE, Anaokar JM, et al. Variability of the Positive
 Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the
 Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. *Radiology*.
 2020;296(1):76-84. doi:10.1148/radiol.2020190646
- Sonn GA, Fan RE, Ghanouni P, et al. Prostate Magnetic Resonance Imaging
 Interpretation Varies Substantially Across Radiologists. *Eur Urol Focus*.
 2019;5(4):592-599. doi:10.1016/j.euf.2017.11.010
- 307 7. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data
 308 System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System
 309 Version 2. *Eur Urol.* 2019;76(3):340-351. doi:10.1016/j.eururo.2019.02.033
- 8. Zhong AY, Digma LA, Hussain T, et al. Automated Patient-level Prostate Cancer
 Detection with Quantitative Diffusion Magnetic Resonance Imaging. *Eur Urol Open Sci.* 2023;47:20-28. doi:10.1016/j.euros.2022.11.009
- 9. Feng CH, Conlin CC, Batra K, et al. Voxel-level Classification of Prostate Cancer on
 Magnetic Resonance Imaging: Improving Accuracy Using FOUR-COMPARTMENT
 Restriction Spectrum Imaging. J Magn Reson Imaging. 2021;54(3):975-984.
- 316 doi:10.1002/jmri.27623
- 10. Lui AJ, Kallis K, Zhong AY, et al. ReIGNITE Radiation Therapy Boost: A Prospective,
 International Study of Radiation Oncologists' Accuracy in Contouring Prostate
 Tumors for Focal Radiation Therapy Boost on Conventional Magnetic Resonance
 Imaging Alone or With Assistance of Restriction Spectrum Imaging. *Int J Radiat*Oncol Biol Phys. 2023;117(5):1145-1152. doi:10.1016/j.ijrobp.2023.07.004

- 322 11. Boschheidgen M, Albers P, Schlemmer HP, et al. Multiparametric Magnetic
 323 Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results
 324 from the First Screening Round of the PROBASE Trial. *Eur Urol*. Published online
 325 October 2023:S0302283823031585. doi:10.1016/j.eururo.2023.09.027
- Thai JN, Narayanan HA, George AK, et al. Validation of PI-RADS Version 2 in
 Transition Zone Lesions for the Detection of Prostate Cancer. *Radiology*.
 2018;288(2):485-491. doi:10.1148/radiol.2018170425
- 329 13. Gielchinsky I, Scheltema MJ, Cusick T, et al. Reduced sensitivity of multiparametric
 330 MRI for clinically significant prostate cancer in men under the age of 50. *Res Rep* 331 *Urol.* 2018;10:145-150. doi:10.2147/RRU.S169017
- 14. White NS, McDonald CR, Farid N, et al. Diffusion-Weighted Imaging in Cancer:
 Physical Foundations and Applications of Restriction Spectrum Imaging. *Cancer Res.* 2014;74(17):4638-4652. doi:10.1158/0008-5472.CAN-13-3534
- 15. Zhuang J, Hrabe J, Kangarlu A, et al. Correction of eddy-current distortions in
 diffusion tensor images using the known directions and strengths of diffusion
 gradients. J Magn Reson Imaging. 2006;24(5):1188-1193. doi:10.1002/jmri.20727
- 16. Karunamuni RA, Kuperman J, Seibert TM, et al. Relationship between kurtosis and
 bi-exponential characterization of high b-value diffusion-weighted imaging:
 application to prostate cancer. *Acta Radiol.* 2018;59(12):1523-1529.
 doi:10.1177/0284185118770889
- 342 17. Holland D, Kuperman JM, Dale AM. Efficient correction of inhomogeneous static
 343 magnetic field-induced distortion in Echo Planar Imaging. *NeuroImage*.
 344 2010;50(1):175-183. doi:10.1016/j.neuroimage.2009.11.044
- 345 18. Conlin CC, Feng CH, Rodriguez-Soto AE, et al. Improved Characterization of
 346 Diffusion in Normal and Cancerous Prostate Tissue Through Optimization of
 347 Multicompartmental Signal Models. *J Magn Reson Imaging*. 2021;53(2):628-639.
 348 doi:10.1002/jmri.27393
- 349 19. White NS, Dale AM. Distinct effects of nuclear volume fraction and cell diameter on
 350 high b-value diffusion MRI contrast in tumors: Diffusion in Tumor Cells. *Magn Reson* 351 *Med*. 2014;72(5):1435-1443. doi:10.1002/mrm.25039
- 20. White NS, Leergaard TB, D'Arceuil H, Bjaalie JG, Dale AM. Probing tissue
 microstructure with restriction spectrum imaging: Histological and theoretical
 validation. *Hum Brain Mapp*. 2013;34(2):327-346. doi:10.1002/hbm.21454
- 21. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological
 Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic
 Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
 Am J Surg Pathol. 2016;40(2):244-252. doi:10.1097/PAS.00000000000530

- 22. Hamdy Freddie C., Donovan Jenny L., Lane J. Athene, et al. Fifteen-Year Outcomes
 after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. *N Engl J Med*.
 2023;388(17):1547-1558. doi:10.1056/NEJMoa2214122
- 362 23. Menne Guricová K, Groen V, Pos F, et al. Risk Modeling for Individualization of the
 363 FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With
 364 Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2024;118(1):66-73.
 365 doi:10.1016/j.ijrobp.2023.07.044
- 24. Lillard Jr JW, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with
 prostate cancer: A literature review. *Cancer*. 2022;128(21):3787-3795.
 doi:10.1002/cncr.34433
- 25. Pagadala MS, Lynch J, Karunamuni R, et al. Polygenic risk of any, metastatic, and
 fatal prostate cancer in the Million Veteran Program. *J Natl Cancer Inst.*2023;115(2):190-199. doi:10.1093/jnci/djac199
- 372 26. Norris JM, Carmona Echeverria LM, Bott SRJ, et al. What Type of Prostate Cancer Is
 373 Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An
 374 Analysis from the PROMIS Cohort. *Eur Urol.* 2020;78(2):163-170.
 375 doi:10.1016/j.eururo.2020.04.029
- 27. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy
 for Prostate-Cancer Diagnosis. *N Engl J Med*. 2018;378(19):1767-1777.
 doi:10.1056/NEJMoa1801993
- 28. Rouvière O, Puech P, Renard-Penna R, et al. Use of prostate systematic and
 targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRIFIRST): a prospective, multicentre, paired diagnostic study. *Lancet Oncol.*2019;20(1):100-109. doi:10.1016/S1470-2045(18)30569-2
- 29. Ahdoot M, Wilbur AR, Reese SE, et al. MRI-Targeted, Systematic, and Combined
 Biopsy for Prostate Cancer Diagnosis. *N Engl J Med*. 2020;382(10):917-928.
 doi:10.1056/NEJMoa1910038
- 386 30. Eklund M, Jäderling F, Discacciati A, et al. MRI-Targeted or Standard Biopsy in
 387 Prostate Cancer Screening. *N Engl J Med*. 2021;385(10):908-920.
 388 doi:10.1056/NEJMoa2100852
- 389 31. Hugosson J, Månsson M, Wallström J, et al. Prostate Cancer Screening with PSA and
 390 MRI Followed by Targeted Biopsy Only. *N Engl J Med*. 2022;387(23):2126-2137.
 391 doi:10.1056/NEJMoa2209454
- 392 32. Klotz L, Chin J, Black PC, et al. Comparison of Multiparametric Magnetic Resonance
 393 Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for
 394 Biopsy-Naive Men at Risk for Prostate Cancer. JAMA Oncol. 2021;7(4):534-542.
 395 doi:10.1001/jamaoncol.2020.7589

- 33. Kerkmeijer LGW, Groen VH, Pos FJ, et al. Focal Boost to the Intraprostatic Tumor in
 External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results
 From the FLAME Randomized Phase III Trial. J Clin Oncol Off J Am Soc Clin Oncol.
 2021;39(7):787-796. doi:10.1200/JCO.20.02873
- 400 34. Groen VH, Haustermans K, Pos FJ, et al. Patterns of Failure Following External Beam
 401 Radiotherapy With or Without an Additional Focal Boost in the Randomized
 402 Controlled FLAME Trial for Localized Prostate Cancer. *Eur Urol.* 2022;82(3):252-257.
 403 doi:10.1016/j.eururo.2021.12.012
- 404 35. Dornisch AM, Zhong AY, Poon DMC, Tree AC, Seibert TM. Focal radiotherapy boost
 405 to MR-visible tumor for prostate cancer: a systematic review. *World J Urol.*406 2024;42(1):56. doi:10.1007/s00345-023-04745-w
- 407 36. Yamin G, Schenker-Ahmed NM, Shabaik A, et al. Voxel Level Radiologic–Pathologic
 408 Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in
 409 Prostate Cancer. *Clin Cancer Res.* 2016;22(11):2668-2674. doi:10.1158/1078410 0432.CCR-15-2429
- 37. James ND, Tannock I, N'Dow J, et al. The Lancet Commission on prostate cancer:
 planning for the surge in cases. *Lancet Lond Engl.* 2024;403(10437):1683-1722.
 doi:10.1016/S0140-6736(24)00651-2
- 38. Chatterjee A, Mercado C, Bourne RM, et al. Validation of Prostate Tissue
 Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic
 Findings. *Radiology*. 2022;302(2):368-377. doi:10.1148/radiol.2021204459
- 39. Singh S, Rogers H, Kanber B, et al. Avoiding Unnecessary Biopsy after
 Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.
- 419 *Radiology*. 2022;305(3):623-630. doi:10.1148/radiol.212536
- 40. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating
 confirmatory study. *The Lancet*. 2017;389(10071):815-822. doi:10.1016/S01406736(16)32401-1
- 424

Figures





anatomical T2W images, and whole-mount histopathology for three representative patients who underwent radical prostatectomy within 6 months of MRI. The RSI maps highlight the areas where clinically significant prostate cancer (csPCa) was confirmed on whole-mount histopathology. All three patients had PI-RADS 4 lesions in the peripheral zone (green arrows). Prostatectomy results showed that patient A had Gleason 4+4 prostate cancer (grade group 4), while patients B and C had Gleason 4+3 cancer (grade group 3).



Tables

CohortsUC San Diego Health693UC San Diego CTIPM679Harvard University's Massachusetts General Hospital (MGH)64University of Rochester Medical Center (URMC)251UC San Francisco (UCSF)43UT Health Sciences Center San Antonio (UTHSCSA)147University of Cambridge15Collincial Parameters70 (64-75)PSA (ng/ml), median (IQR)6.36 (4.65-9.20)Prostate volume (ml), median (IQR)6.36 (4.65-9.20)Prostate volume (ml), median (IQR)6.36 (4.65-9.20)Prostate volume (ml), median (IQR)6.37 (16-74)PSA density (ng/ml ²), median (IQR)6.37Biopsy0.11 (0.07-0.19)Blopsy657Systematic biopsy prior to MRI scan667Biopsy-naive at time of MRI scan (had a biopsy within 6 months after MRI)1235 (877)Pathology710Systematic biopsy only503Targeted biopsy only503Targeted biopsy only503Targeted biopsy only503Prabatectormy323No biopsy within 6 months of MRI scan500PP-RADS (v2.1)1163625332634443Out available*443Out available*443Genese Grade Group2962367321148115103Race & Ethnicity94White, Hispanic94White, Hispanic<	Patient Characteristics. Total Study Participants (n = 1892)	
UC San Diego Health663UC San Diego CTIPM679Harvard University's Massachusetts General Hospital (MGH)64University of Rochester Medical Center (URMC)251UC San Francisco (UCSF)43UT Health Sciences Center San Antonio (UTHSCSA)147University of Cambridge15Clinical Parameters70 (64-75)Age (years), median (IQR)6.36 (4.65-9.20)Prostate volume (ml), median (IQR)6.11 (0.07-0.19)Biopsy70Prostate volume (ml), median (IQR)51 (36-74)PSA density (ng/ml²), median (IQR)657Biopsy-nalve at time of MRI scan (had a biopsy within 6 months after MRI)125 (677)Pathology710Prostate to biopsy prior to MRI scan (had a biopsy within 6 months after MRI)125 (677)Pathology710Prostate to biopsy only503Targeted biopsy only323No biopsy within 6 months of MRI scan500PI-RADS (v2.1)6361636253323244335443Not available*443Benign33412962367321114815103Race & Ethnicity94White, Hispanic94White, Chron-Ilspanic120Back or African American120	Cohorts	
UC San Diego CTIPM679Harvard University's Massachusetts General Hospital (MGH)64University of Rochester Medical Center (URMC)251UC San Francisco (UCSF)43UT Health Sciences Center San Antonio (UTHSCSA)147University of Cambridge15Clinical Parameters70 (64-75)PSA (ng/ml), median (IQR)6.36 (4.65-9.20)Prostate volume (ml), median (IQR)0.11 (0.07-0.19)Biopsy657Received biopsy prior to MRI scan657Biopsy-naïve at time of MRI scan (had a biopsy within 6 months after MRI)1235 (877)Pathology710Prostate volume (ml, medien KIR)503Targeted biopsy only179Systematic biopsy only503Targeted biopsy only710Prostatectomy323No biopsy within 6 months of MRI scan650Pirostatectomy323No biopsy within 6 months of MRI scan636253326334443Benign3341296236732114815103Race & Ethnicity94White, Hispanic94White, Hispanic94White, Christor Vulnown65Asian120Back or African American117	UC San Diego Health	693
Harvard University's Massachusetts General Hospital (MGH)64University of Rochester Medical Center (URMC)251UC San Francisco (UCSF)43UT Health Sciences Center San Antonio (UTHSCSA)147University of Cambridge15Clinical Parameters70 (64-75)Age (years), median (IQR)6.36 (4.65-9.20)Prostate volume (ml), median (IQR)51 (36-74)PSA density (ng/ml²), median (IQR)0.11 (0.07-0.19)Biopsy8Received biopsy prior to MRI scan657Biopsy-naïve at time of MRI scan (had a biopsy within 6 months after MRI)1235 (877)Pathology710Systematic biopsy only503Targeted biopsy only503Targeted biopsy only323No biopsy within 6 months of MRI scan500PI-RADS (v2.1)636163625332634443Not available*443Not available*246434112962367324815103Race & Ethnicity94White, Hispanic94White, Ethnicity Other / Unknown65Asian120Back or African American117	UC San Diego CTIPM	679
University of Rochester Medical Center (URMC)251UC San Francisco (UCSF)43UT Health Sciences Center San Antonio (UTHSCSA)147University of Cambridge15Clinical Parameters70 (64-75)PSA (ng/ml), median (IQR)6.36 (4.65-9.20)Prostate volume (ml), median (IQR)6.13 (64-74)PSA density (ng/ml²), median (IQR)0.11 (0.07-0.19)Biopsy8Received biopsy prior to MRI scan657Biopsy-naïve at time of MRI scan (had a biopsy within 6 months after MRI)1235 (877)Pathology503Targeted biopsy only503Targeted biopsy only503Targeted biopsy only503No biopsy within 6 months after MRI)1235 (877)Pystematic and targeted biopsy710Prostatectomy323No biopsy within 6 months of MRI scan500PI-RADS (v2.1)6361636253326534443Ceasen Grade Group444Benign334122662367321114815103Race & Ethnicity94White, Hispanic94White, Ethnicity Other / Unknown65Saian120Black or African American117	Harvard University's Massachusetts General Hospital (MGH)	64
UC San Francisco (UCSF)43UT Health Sciences Center San Antonio (UTHSCSA)147University of Cambridge15Clinical Parameters70 (64-75)Age (years), median (IQR)6.36 (4.65-9.20)Prostate volume (ml), median (IQR)51 (36-74)PSA density (ng/ml²), median (IQR)0.11 (0.07-0.19)Biopsy8Received biopsy prior to MRI scan657Biopsy-naïve at time of MRI scan (had a biopsy within 6 months after MRI)1235 (877)Pathology503Targeted biopsy only503Targeted biopsy only503Targeted biopsy only503Prostatectomy323No biopsy within 6 months of MRI scan500PP-RDS (v2.1)6361636253326534443Cleason Grade Group443Benign3341296236732114815103Race & Ethnicity94White, Hispanic94White, Ethnicity Other / Unknown65Saian120Back or African American117	University of Rochester Medical Center (URMC)	251
UT Health Sciences Center San Antonio (UTHSCSA) 147 University of Cambridge 15 CLinical Parameters 70 (64-75) Age (years), median (IQR) 6.36 (4.65-9.20) Prostate volume (mI), median (IQR) 51 (36-74) PSA density (ng/ml ²), median (IQR) 0.11 (0.07-0.19) Biopsy 0.11 (0.07-0.19) Biopsy 657 Biopsy-naive at time of MRI scan 657 Biopsy-naive at time of MRI scan (had a biopsy within 6 months after MRI) 1235 (877) Pathology 503 Systematic biopsy only 503 Targeted biopsy only 503 Systematic and targeted biopsy 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 1 1 636 2 53 3 2663 4 443 Not available* 443 Seen Grade Group 334 1 296 2 367 3 211 </td <td>UC San Francisco (UCSF)</td> <td>43</td>	UC San Francisco (UCSF)	43
University of Cambridge 15 Clinical Parameters 70 (64-75) Age (years), median (IQR) 6.36 (4.65-9.20) Prostate volume (ml), median (IQR) 51 (36-74) PSA (ng/ml ²), median (IQR) 0.11 (0.07-0.19) Biopsy 0.11 (0.07-0.19) Biopsy 657 Biopsy-naïve at time of MRI scan 657 Biopsy-naïve at time of MRI scan (had a biopsy within 6 months after MRI) 1235 (877) Pathology 710 Systematic biopsy only 503 Targeted biopsy only 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 1 636 2 53 3 2633 4 443 Not available* 443 Not available* 444 Geason Grade Group 296 2 3667 3 211 4 81 5 1003 Race & Ethnicity 94 <td>UT Health Sciences Center San Antonio (UTHSCSA)</td> <td>147</td>	UT Health Sciences Center San Antonio (UTHSCSA)	147
Clinical Parameters Age (years), median (IQR) 70 (64-75) PSA (ng/ml), median (SD) 6.36 (4.65-9.20) Prostate volume (ml), median (IQR) 51 (36-74) PSA density (ng/ml ²), median (IQR) 0.11 (0.07-0.19) Biopsy 8 Received biopsy prior to MRI scan 657 Biopsy-naive at time of MRI scan (had a biopsy within 6 months after MRI) 1235 (877) Pathology 503 Systematic biopsy only 503 Targeted biopsy only 503 Systematic and targeted biopsy 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 1 636 2 53 3 2663 4 443 Not available* 444 Cleason Grade Group 296 2 367 3 211 4 103 Race & Ethnicity 94 White, Hispanic 94 White, Ethnicity Other / Un	University of Cambridge	15
Age (years), median (IQR) 70 (64-75) PSA (ng/ml), median (SD) 6.36 (4.65-9.20) Prostate volume (ml), median (IQR) 51 (36-74) PSA density (ng/ml ²), median (IQR) 0.11 (0.07-0.19) Biopsy 657 Biopsy-naïve at time of MRI scan (had a biopsy within 6 months after MRI) 1235 (877) Pathology 503 Targeted biopsy only 503 Targeted biopsy only 503 Targeted biopsy only 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 666 2 53 3 263 4 453 5 443 Notavilable* 444 Geason Grade Group 296 2 367 3 211 4 296 2 367 3 211 4 296 2 367 3 211 4 103 Reage Graup 103	Clinical Parameters	
PSA (ng/ml), median (SD) 6.36 (4.65-9.20) Prostate volume (ml), median (IQR) 51 (36-74) PSA density (ng/ml²), median (IQR) 0.11 (0.07-0.19) Biopsy 8 Received biopsy prior to MRI scan 657 Biopsy-naïve at time of MRI scan (had a biopsy within 6 months after MRI) 1235 (877) Pathology 503 Systematic biopsy only 503 Targeted biopsy only 179 Systematic and targeted biopsy 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 1 636 2 53 3 263 4 453 5 443 Not available* 444 Stand Grade Group 296 2 367 367 3 211 4 4 81 5 5 103 367 3 211 4 4 81 5	Age (years), median (IQR)	70 (64-75)
Prostate volume (ml), median (IQR) 51 (36-74) PSA density (ng/ml²), median (IQR) 0.11 (0.07-0.19) Biopsy 657 Biopsy-naïve at time of MRI scan (had a biopsy within 6 months after MRI) 1235 (877) Pathology 503 Targeted biopsy only 503 Targeted biopsy only 503 Systematic biopsy only 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 1 636 2 53 3 2633 4 453 5 443 Not available* 444 Cleason Grade Group 334 1 296 2 367 3 211 4 41 Cleason Grade Group 211 4 81 5 103 6 94 White, Hispanic 94 White, Sthnicity Other / Unknown 65 <	PSA (ng/ml), median (SD)	6.36 (4.65-9.20)
PSA density (ng/ml²), median (IQR) 0.11 (0.07-0.19) Biopsy 657 Biopsy-naive at time of MRI scan (had a biopsy within 6 months after MRI) 1235 (877) Pathology 503 Systematic biopsy only 503 Targeted biopsy only 503 Systematic and targeted biopsy 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 1 636 2 53 3 263 4 453 5 443 Not available* 444 Gleason Grade Group 334 1 296 2 367 3 211 4 81 5 103 Race & Ethnicity 94 White, Non-Hispanic 120 Back or African American 117	Prostate volume (ml), median (IQR)	51 (36-74)
Biopsy657Received biopsy prior to MRI scan (had a biopsy within 6 months after MRI)1235 (877)Pathology503Systematic biopsy only503Targeted biopsy only179Systematic and targeted biopsy710Prostatectomy323No biopsy within 6 months of MRI scan500PI-RADS (v2.1)11636253326344535443Not available*44Cleason Grade Group32483341296236732114815103Race & Ethnicity94White, Hispanic94White, Ethnicity Other / Unknown65Asian120Black or African American117	PSA density (ng/ml²), median (IQR)	0.11 (0.07-0.19)
Received biopsy prior to MRI scan (had a biopsy within 6 months after MRI) 1235 (877) Pathology 503 Systematic biopsy only 503 Targeted biopsy only 179 Systematic and targeted biopsy 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 1 636 2 53 3 263 4 453 5 443 Not available* 44 Gleason Grade Group 334 1 296 2 367 3 211 4 296 2 367 3 211 4 31 5 103 Rece & Ethnicity 94 White, Hispanic 94 White, Ethnicity Other / Unknown 65 Asian 120 Back or African American 117	Biopsy	
Biopsy-naïve at time of MRI scan (had a biopsy within 6 months after MRI) 1235 (877) Pathology 503 Systematic biopsy only 503 Targeted biopsy only 179 Systematic and targeted biopsy 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 2 53 3 2633 4 453 5 443 Not available* 444 Cleason Grade Group 334 1 296 2 367 3 211 4 296 2 367 3 211 4 81 5 103 Race & Ethnicity 94 White, Hispanic 94 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	Received biopsy prior to MRI scan	657
Pathology 503 Systematic biopsy only 503 Targeted biopsy only 179 Systematic and targeted biopsy 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 2 53 3 263 4 453 5 443 Not available* 44 Cleason Grade Group 334 1 296 2 367 3 211 4 81 5 103 Race & Ethnicity 94 White, Hispanic 94 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	Biopsy-naïve at time of MRI scan (had a biopsy within 6 months after MRI)	1235 (877)
Systematic biopsy only 503 Targeted biopsy only 179 Systematic and targeted biopsy 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 2 53 3 263 4 453 5 443 Not available* 44 Cleason Grade Group 334 1 296 2 367 3 211 4 81 5 103 Race & Ethnicity 94 White, Hispanic 94 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	Pathology	
Targeted biopsy only 179 Systematic and targeted biopsy 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 2 53 3 263 4 453 5 443 Not available* 44 Cleason Grade Group 334 1 296 2 367 3 211 4 296 2 367 3 211 4 296 2 367 3 211 4 81 5 103 Race & Ethnicity 94 White, Hispanic 94 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	Systematic biopsy only	503
Systematic and targeted biopsy 710 Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 2 53 3 263 4 453 5 443 Not available* 443 Benign 334 1 296 2 367 3 211 4 81 5 103 Race & Ethnicity 94 White, Hispanic 94 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	Targeted biopsy only	179
Prostatectomy 323 No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 1 636 2 53 3 263 4 453 5 443 Not available* 44 Gleason Grade Group 367 3 211 4 296 2 367 3 103 Race & Ethnicity 94 White, Hispanic 94 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	Systematic and targeted biopsy	710
No biopsy within 6 months of MRI scan 500 PI-RADS (v2.1) 636 1 636 2 53 3 263 4 453 5 443 Not available* 443 Benign 334 1 296 2 367 3 211 4 296 2 367 3 211 4 81 5 103 Race & Ethnicity 94 White, Hispanic 94 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	Prostatectomy	323
PI-RADS (v2.1) 636 1 636 2 53 3 263 4 453 5 443 Not available* 444 Gleason Grade Group 334 1 296 2 367 3 211 4 81 5 103 Race & Ethnicity 94 White, Hispanic 94 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	No biopsy within 6 months of MRI scan	500
1 636 2 53 3 263 4 453 5 443 Not available* 44 Gleason Grade Group Benign 334 1 296 2 367 3 211 4 81 5 103 Race & Ethnicity 94 White, Hispanic 94 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	PI-RADS (v2.1)	
2 53 3 263 4 453 5 443 Not available* 44 Gleason Grade Group Benign 334 1 296 2 367 3 211 4 81 5 103 Race & Ethnicity 94 White, Non-Hispanic 1228 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	1	636
3 263 4 453 5 443 Not available* 44 Gleason Grade Group Benign 334 1 296 2 367 3 211 4 81 5 103 Race & Ethnicity 94 White, Hispanic 94 White, Non-Hispanic 1228 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	2	53
4 453 5 443 Not available* 44 Gleason Grade Group Benign 334 1 296 2 367 3 211 4 81 5 103 Race & Ethnicity 94 White, Hispanic 94 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	3	263
5443Not available*44Gleason Grade GroupBenign3341296236732114815103Race & EthnicityWhite, Hispanic94White, Non-Hispanic1228White, Ethnicity Other / Unknown65Asian120Black or African American117	4	453
Not available*44Gleason Grade GroupBenign3341296236732114815103Race & Ethnicity94White, Hispanic94White, Non-Hispanic1228White, Ethnicity Other / Unknown65Asian120Black or African American117	5	443
Gleason Grade GroupBenign3341296236732114815103Race & EthnicityWhite, Hispanic94White, Non-Hispanic1228White, Ethnicity Other / Unknown65Asian120Black or African American117	Not available*	44
Benign 334 1 296 2 367 3 211 4 81 5 103 Race & Ethnicity White, Hispanic 94 White, Non-Hispanic 1228 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	Gleason Grade Group	
1 296 2 367 3 211 4 81 5 103 Race & Ethnicity White, Hispanic 94 White, Non-Hispanic 1228 White, Ethnicity Other / Unknown 65 Asian 120 Black or African American 117	Benign	334
236732114815103Race & EthnicityWhite, Hispanic94White, Non-Hispanic1228White, Ethnicity Other / Unknown65Asian120Black or African American117	1	296
32114815103Race & EthnicityWhite, Hispanic94White, Non-Hispanic1228White, Ethnicity Other / Unknown65Asian120Black or African American117	2	367
4815103Race & Ethnicity94White, Hispanic94White, Non-Hispanic1228White, Ethnicity Other / Unknown65Asian120Black or African American117	3	211
5103Race & Ethnicity94White, Hispanic94White, Non-Hispanic1228White, Ethnicity Other / Unknown65Asian120Black or African American117	4	81
Race & EthnicityWhite, Hispanic94White, Non-Hispanic1228White, Ethnicity Other / Unknown65Asian120Black or African American117	5	103
White, Hispanic94White, Non-Hispanic1228White, Ethnicity Other / Unknown65Asian120Black or African American117	Race & Ethnicity	
White, Non-Hispanic1228White, Ethnicity Other / Unknown65Asian120Black or African American117	White, Hispanic	94
White, Ethnicity Other / Unknown65Asian120Black or African American117	White, Non-Hispanic	1228
Asian 120 Black or African American 117	White, Ethnicity Other / Unknown	65
Black or African American 117	Asian	120
	Black or African American	117

American Indian/Alaska Native	6	
Native Hawaiian or Other Pacific Islander	6	
Other / Unknown	256	
Table 1. Characteristics of the patients included in this study. *	Scans with no PI-R	ADS
available were research-only scans. CTIPM = Center for Translation	al Imaging and Preci	sion
Medicine. UC = University of California. UT = University of Texas. PSA = prostate-specific		

antigen. PI-RADS = Prostate Imaging Reporting & Data System.

	AUCs for csPCa discrimination in multivariable models			
Test Group	RSIrs PI-RADS ADC RSIrs, PI-RADS*			
A) GG ≥ 2 cancer	0.72 [0.68-0.76]	0.74 [0.70-0.77]	0.54 [0.50-0.59]	0.77 [0.73-0.81]
B) GG2 cancer	0.69 [0.64-0.74]	0.69 [0.64-0.73]	0.53 [0.50-0.58]	0.73 [0.68-0.77]
C) GG3 cancer	0.72 [0.66-0.78]	0.74 [0.69-0.79]	0.54 [0.50-0.60]	0.78 [0.72-0.83]
D) GG4-5 cancer	0.80 [0.73-0.86]	0.85 [0.80-0.89]	0.58 [0.51-0.65]	0.87 [0.82-0.92]
	PSA, Age	PSAD, Age, RSIrs	PSAD, Age, RSIrs, PI-RADS*	PSAD, Age, Race, RSIrs, PI-RADS*
A) GG ≥ 2 cancer	0.61 [0.56-0.66]	0.74 [0.70-0.77]	0.78 [0.74-0.82]	0.78 [0.74-0.82]
B) GG2 cancer	0.53 [0.50-0.58]	0.69 [0.64-0.74]	0.73 [0.69-0.78]	0.74 [0.69-0.78]
C) GG3 cancer	0.65 [0.57-0.72]	0.73 [0.67-0.79]	0.78 [0.72-0.83]	0.78 [0.72-0.83]
D) GG4-5 cancer	0.77 [0.70-0.83] 0.86 [0.81-0.91] 0.90 [0.85-0.94] 0.90 [0.85-0.94]			

Table 2. Results from the multivariable logistic regression models for combinations of RSIrs with clinical and imaging parameters for discrimination of clinically significant prostate cancer (csPCa, grade group [GG] \geq 2). Group A) independent testing in all biopsy-naïve patients at time of MRI with biopsy confirmed diagnosis who were not used for training (n=664); comparison is csPCa vs. no csPCa (benign or grade group 1, GG1). Group B) GG2 vs. non-csPCa: subset of independent testing dataset with either GG2 csPCa or no csPCa (n=500). Group C) GG3 vs.

independent testing dataset with either GG2 csPCa or no csPCa (n=500). Group C) GG3 vs. non-csPCa: subset of independent testing dataset with either GG3 csPCa or no csPCa (n=409). Group D) GG4-5 vs. no csPCa: subset of independent testing dataset with GG4 csPCa, GG5 csPCa, or no csPCa (n=393). 95% confidence intervals were calculated from 10,000-bootsrapping stratified by csPCa.

Supplementary Material



Supplementary Figure 1. A) Histogram of RSIrs values in all patients in the study. B) Histogram of RSIrs values in patients who were biopsy-naïve at time of MRI.

RSI model formula	RSI compartment	Fixed Diffusion Coefficient (s/mm ²)
4	Restricted Diffusion (\mathcal{C}_1)	$1.1 * 10^{-4} (D_1)$
$(h) = \sum_{i=1}^{4} C_{i} e^{-bD_{i}}$	Hindered Diffusion (C_2)	$1.8 * 10^{-3} (D_2)$
$(b) = \sum_{i=1}^{n} c_i e^{-i t}$	Free Diffusion (C_3)	$3.6 * 10^{-3} (D_3)$
<i>l</i> =1	Vascular Flow (C_4)	0.1220 (<i>D</i> ₄)

Supplementary Table 1. The RSI model computes the sum of DWI signal from the four compartments as expressed by the formula above. S(b) represents the measured diffusion-weighted imaging (DWI) signal intensity at a specific *b*-value. The signal is modeled as a linear combination of exponential decays, each corresponding to one of four diffusion compartments. C_i denotes the signal contribution of a particular compartment to the overall signal; these contributions are determined through model-fitting. The diffusion coefficients, D_i , are set to empirically determined values for each of the four tissue compartments (C_i).

UCSD CTIPM	DWI	T ₂ -weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	4500	7000
TE (ms)	69	100
FOV (mm)	240 x 120	240 x 240
Matrix	06 y 40 [100 y 100]	220 y 220 [E12 y E12]
[resampled dimensions]	96 X 48 [126 X 126]	320 x 320 [512 x 512]
Slices	16	32
Slice Thickness (mm)	6	3
<i>b</i> -values (s/mm ²)	0[1], 500[6],	N1/A
[number of samples]	1000[6], 2000[12]	N/A
Field Strength (T)	3	3

UCSD Health	DWI	T ₂ -weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	4000	5300
TE (ms)	69	100
FOV (mm)	240 x 120	200 x 200
Matrix	06 × 48 [266 × 266]	220 x 220 [E12 x E12]
[resampled dimensions]	96 X 48 [236 X 236]	320 x 320 [512 x 512]
Slices	16	32
Slice Thickness (mm)	6	3
<i>b</i> -values (s/mm ²)	0[1], 500[8],	
[number of samples]	1000[8], 2000[16]	IN/A
Field Strength (T)	3	3

URMC	DWI	T2-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	3800	4800
TE (ms)	85	104
FOV (mm)	52 x 52	180x180
Matrix	100 x 52 [104 x 200]	204 y 205 [204 y 204]
[resampled dimensions]	100 x 52 [104 x 200]	364 X 363 [364 X 364]
Slices	22	32
Slice Thickness (mm)	4	3
<i>b</i> -values (s/mm ²)	0[1], 500[6],	
[number of samples]	1000[6], 2000[6]	IN/A
Field Strength (T)	3	3

DWI	T ₂ -weighted
Diffusion-weighted EPI	Fast Spin Echo (FSE)
4500	3937
59	169
240 x 120	160 x 160
06 y 40 [100y100]	360 x 224
96 X 48 [128X 128]	[1024 x 1024]
16	40
6	3
0[1], 500[6],	NI/A
1000[6], 2000[12]	IN/A
3	3
	DWI Diffusion-weighted EPI 4500 59 240 x 120 96 x 48 [128x128] 16 6 0[1], 500[6], 1000[6], 2000[12] 3

Cambridge	DWI	T2-weighted
Pulse sequence	Diffusion-weighted	d EPI Fast Spin Echo (FSE)

TR (ms)	4500	3130
TE (ms)	68	98
FOV (mm)	220 x 110	180 x 180
Matrix [resampled dimensions]	96 x 48 [256 x 256]	448 x 256 [512 x 512]
Slices	8	30
Slice Thickness (mm)	4	3
<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[2], 1000[2], 2000[4]	N/A
Field Strength (T)	3	3

UTHSCSA	DWI	T ₂ -weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	6300	4710
TE (ms)	105	100
FOV (mm)	52 x 100	180 x 180
Matrix	E2 x 100 x [104 x 200]	240 x 220 x [220 x 220]
[resampled dimensions]	52 x 100 x [104 x 200]	240 X 320 X [320 X 320]
Slices	22	30
Slice Thickness (mm)	4	3
<i>b</i> -values (s/mm ²)	0[1], 500[6],	N1/A
[number of samples]	1000[18], 2000[42]	N/A
Field Strength (T)	3	3

UCSF	DWI	T ₂ -weighted	
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)	
TR (ms)	4500	2964	
TE (ms)	73	150	
FOV (mm)	200 x 200	220 x 220	
Matrix		E10 y E10 [200 y 200]	
[resampled dimensions]	236 X 236 [236 X 236]	512 x 512 [520 x 520]	
Slices	35	36	
Slice Thickness (mm)	3	3	
<i>b</i> -values (s/mm²)	0[5], 100[6], 800[12],		
[number of samples]	1400[12], 2500[18]	IN/A	
Field Strength (T)	3	3	

Institution	Scanner models	Number of Stations
UCSD CTIPM	GE Healthcare Discovery MR750,	4
	GE Healthcare Signa Premier	
UCSD Health	GE Healthcare Discovery MR750,	4
	GE Healthcare Signa Premier	
URMC	SIEMENS Skyra	2
MGH	GE Healthcare Signa Premier	1
UCSF	GE Healthcare Signa Premier	2
Cambridge	GE Healthcare Discovery MR750	1
UTHSCSA	SIEMENS Skyra	3
Total	3 scanner models	17 stations

Supplementary Table 2. MRI acquisition parameters for each cohort. Parameters such as echo time (TE), repetition time (TR), matrix acquisition or slice thickness differ between RSI protocols. FOV: field-of-view. FSE: fast spin echo. EPI: echo-planar imaging. DWI: diffusion-weighted imaging. UCSD: University of California San Diego. CTIPM: Center for Translational Imaging and Precision Medicine. MGH: Harvard University's Massachusetts General Hospital. URMC: University of Rochester Medical Center. UTHSCSA: University

of Texas Health Sciences Center San Antonio. UCSF: University of California San Francisco. Cambridge: University of Cambridge.

434 435 436

> % with **Patient Cohort** n AUC RSIrs AUC PI-RADS AUC ADC csPCa GG≥2 877 55 0.73 [0.69,0.76] 0.75 [0.71,0.78] 0.54 [0.50,0.57] GG≥3 0.76 [0.72,0.80] 0.79 [0.76,0.82] 0.55 [0.50,0.60] 642 38 GG 2 only 633 37 0.69 [0.65,0.73] 0.70 [0.66,0.74] 0.52 [0.48,0.57] GG 3 only 531 25 0.73 [0.68,0.77] 0.75 [0.71,0.80] 0.53 [0.48,0.59] 0.80 [0.74,0.85] GG 4-5 only 509 22 0.83 [0.79,0.87] 0.57 [0.51,0.63] TZ csPCa 329 43 0.72 [0.66,0.78] 0.72 [0.66,0.77] 0.57 [0.51,0.63] PZ csPCa 602 55 0.72 [0.68,0.76] 0.76 [0.73,0.80] 0.52 [0.48,0.57] 0.79 [0.69,0.87] < 60 years old 103 45 0.70 [0.60,0.79] 0.57 [0.45,0.68] ≥ 60 years old 772 56 0.72 [0.68,0.75] 0.75 [0.72,0.78] 0.53 [0.49,0.57] **Race White** 672 0.74 [0.70,0.77] 0.54 [0.49,0.58] 53 0.76 [0.72,0.79] Race Asian 64 0.74 [0.59,0.87] 0.78 [0.64,0.89] 0.62 [0.44,0.79] 47 **Race Black** 51 45 0.68 [0.53,0.82] 0.60 [0.46,0.74] 0.54 [0.38,0.70] Race Other / Unknown 107 64 0.70 [0.59,0.80] 0.72 [0.62,0.80] 0.57 [0.45,0.68]

	p-value RSIrs vs. PI-RADS	p-value RSIrs vs. ADC
GG≥2	0.31	<0.01
GG≥3	0.14	<0.01
GG 2 only	0.75	<0.01
GG 3 only	0.31	<0.01
GG 4-5 only	0.20	<0.01
TZ csPCa	0.90	<0.01
PZ csPCa	0.07	<0.01
< 60 years old	0.12	<0.01
≥ 60 years old	0.11	<0.01
Race White	0.32	<0.01
Race Asian	0.61	0.28
Race Black	0.41	0.12
Race Other / Unknown	0.82	0.05

Supplementary Table 3. AUC values for RSIrs, PI-RADS and ADC in different subsets. 95% confidence intervals were calculated from 10,000-bootsrapping stratified by grade group. All cohorts are against non-csPCa (benign and grade group 1). GG: Grade Group.